Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diabetology & Metabolic Syndrome
Published in: Diabetology & Metabolic Syndrome 1/2015

Open Access 01-12-2015 | Meeting abstract

Cortistatin hyperpolarizes pancreatic beta cell membrane and reduces glucose-stimulated insulin secretion

Authors: Alex Rafacho, Manuel Castellano-Muñoz, Paloma Alonso-Magdalena, Esperanza Irles, Melisa Bello, Jean Vetorazzi, Beatriz Merino, Sergi Soriano, Pau Iborra, Antonia Ruiz, Raúl M Luque, Angel Nadal, Ivan Quesada

Published in: Diabetology & Metabolic Syndrome | Special Issue 1/2015

Login to get access

Excerpt

Cortistatin-14 (CORT) is a neuropeptide commonly expressed in inhibitory neurons of the central nervous system (CNS) with structural, pharmacological and functional similarity to somatostatin (SST). In addition to having roles in the CNS, both peptides also regulate endocrine secretion. Yet the cellular mechanisms supporting this role are not well understood. …
Metadata
Title
Cortistatin hyperpolarizes pancreatic beta cell membrane and reduces glucose-stimulated insulin secretion
Authors
Alex Rafacho
Manuel Castellano-Muñoz
Paloma Alonso-Magdalena
Esperanza Irles
Melisa Bello
Jean Vetorazzi
Beatriz Merino
Sergi Soriano
Pau Iborra
Antonia Ruiz
Raúl M Luque
Angel Nadal
Ivan Quesada
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Diabetology & Metabolic Syndrome / Issue Special Issue 1/2015
Electronic ISSN: 1758-5996
DOI
https://doi.org/10.1186/1758-5996-7-S1-A250

Other articles of this Special Issue 1/2015

Diabetology & Metabolic Syndrome 1/2015 Go to the issue

Meeting abstract

Older patients are at increased risk for renal posttransplantation diabetes mellitus

Meeting abstract

In-hospital experience with insulin degludec (IDeg)

Meeting abstract

Energy expenditure changes after Roux-en-Y Gastric Bypass

Meeting abstract

The relationship between plasminogen activator inhibitor-1 and type 2 diabetes: a systematic review and meta-analysis

Meeting abstract

Study of influence of a model guidance about the laboratory tests and disease in knowledge and self-management of patients with type 2 DM

Meeting abstract

HbA1c shows good correlation with regular post-prandial pre-exercise blood glucose measures in active individuals with type 2 diabetes mellitus
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits